Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging.

Masahiro Okada, Yasuharu Imai, Tonsok Kim, Sachiyo Kogita, Manabu Takamura, Seishi Kumano, Hiromitsu Onishi, Masatoshi Hori, Kazuto Fukuda, Norio Hayashi, Kenichi Wakasa, Michiie Sakamoto, Takamichi Murakami

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

To compare enhancenent patterns of hepatocellular carcinoma (HCC) and dysplastic nodule (DN) between gadoxetate- and ferucarbotran-enhanced MRI. Patients recruited from ultrasound surveillance for HCC in chronic liver diseases were enrolled in this prospective study approved by institutional review board. Thirty-six patients with 37 histologically proven HCC, including 22 well-differentiated HCCs (wHCC), 15 moderately to poorly differentiated HCCs (mpHCCs), and 4 DNs, underwent gadoxetate-enhanced and ferucarbotran-enhanced MRI. We compared hepatobiliary phase image of gadoxetate-enhanced MRI with ferucarbotran-enhanced MR image regarding signal intensity of HCC and DN relative to surrounding liver parenchyma. We calculated contrast ratios between tumor and liver on pre-enhancement, hepatobiliary phase of gadoxetate-enhanced MRI and ferucarbotran-enhanced MRI. On ferucarbotran-enhanced MRI, all mpHCCs showed hyper-intensity, while 14 wHCCs (14/22;63%) showed iso-intensity. On hepatobiliary phase of gadoxetate-enhanced MRI, 13 mpHCCs (13/15;86%) and 20 wHCCs (20/22;91%) showed hypo-intensity. Two DNs and the other two showed iso- and hypo-intensity, respectively, on gadoxetate-enhanced MRI, whereas all DNs revealed iso-intensity on ferucarbotran-enhanced MRI. Gadoxetate-postcontrast ratio was significantly lower than ferucarbotran-postcontrast ratio in wHCC (P = 0.015). The uptake function of hepatocytes that are targeted by gadoxetate is more sensitive than that of Kupffer cells targeted by ferucarbotran in stepwise hepatocarcinogenesis.

Original languageEnglish
Pages (from-to)903-913
Number of pages11
JournalJournal of magnetic resonance imaging : JMRI
Volume32
Issue number4
Publication statusPublished - 2010 Oct
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Magnetic Resonance Imaging
Kupffer Cells
ferumoxides
Research Ethics Committees
Liver
Liver Diseases
Hepatocytes
Chronic Disease
Prospective Studies
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging. / Okada, Masahiro; Imai, Yasuharu; Kim, Tonsok; Kogita, Sachiyo; Takamura, Manabu; Kumano, Seishi; Onishi, Hiromitsu; Hori, Masatoshi; Fukuda, Kazuto; Hayashi, Norio; Wakasa, Kenichi; Sakamoto, Michiie; Murakami, Takamichi.

In: Journal of magnetic resonance imaging : JMRI, Vol. 32, No. 4, 10.2010, p. 903-913.

Research output: Contribution to journalArticle

Okada, M, Imai, Y, Kim, T, Kogita, S, Takamura, M, Kumano, S, Onishi, H, Hori, M, Fukuda, K, Hayashi, N, Wakasa, K, Sakamoto, M & Murakami, T 2010, 'Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging.', Journal of magnetic resonance imaging : JMRI, vol. 32, no. 4, pp. 903-913.
Okada, Masahiro ; Imai, Yasuharu ; Kim, Tonsok ; Kogita, Sachiyo ; Takamura, Manabu ; Kumano, Seishi ; Onishi, Hiromitsu ; Hori, Masatoshi ; Fukuda, Kazuto ; Hayashi, Norio ; Wakasa, Kenichi ; Sakamoto, Michiie ; Murakami, Takamichi. / Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging. In: Journal of magnetic resonance imaging : JMRI. 2010 ; Vol. 32, No. 4. pp. 903-913.
@article{f253b64bcb9f457d8585b33ae2a4779f,
title = "Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging.",
abstract = "To compare enhancenent patterns of hepatocellular carcinoma (HCC) and dysplastic nodule (DN) between gadoxetate- and ferucarbotran-enhanced MRI. Patients recruited from ultrasound surveillance for HCC in chronic liver diseases were enrolled in this prospective study approved by institutional review board. Thirty-six patients with 37 histologically proven HCC, including 22 well-differentiated HCCs (wHCC), 15 moderately to poorly differentiated HCCs (mpHCCs), and 4 DNs, underwent gadoxetate-enhanced and ferucarbotran-enhanced MRI. We compared hepatobiliary phase image of gadoxetate-enhanced MRI with ferucarbotran-enhanced MR image regarding signal intensity of HCC and DN relative to surrounding liver parenchyma. We calculated contrast ratios between tumor and liver on pre-enhancement, hepatobiliary phase of gadoxetate-enhanced MRI and ferucarbotran-enhanced MRI. On ferucarbotran-enhanced MRI, all mpHCCs showed hyper-intensity, while 14 wHCCs (14/22;63{\%}) showed iso-intensity. On hepatobiliary phase of gadoxetate-enhanced MRI, 13 mpHCCs (13/15;86{\%}) and 20 wHCCs (20/22;91{\%}) showed hypo-intensity. Two DNs and the other two showed iso- and hypo-intensity, respectively, on gadoxetate-enhanced MRI, whereas all DNs revealed iso-intensity on ferucarbotran-enhanced MRI. Gadoxetate-postcontrast ratio was significantly lower than ferucarbotran-postcontrast ratio in wHCC (P = 0.015). The uptake function of hepatocytes that are targeted by gadoxetate is more sensitive than that of Kupffer cells targeted by ferucarbotran in stepwise hepatocarcinogenesis.",
author = "Masahiro Okada and Yasuharu Imai and Tonsok Kim and Sachiyo Kogita and Manabu Takamura and Seishi Kumano and Hiromitsu Onishi and Masatoshi Hori and Kazuto Fukuda and Norio Hayashi and Kenichi Wakasa and Michiie Sakamoto and Takamichi Murakami",
year = "2010",
month = "10",
language = "English",
volume = "32",
pages = "903--913",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging.

AU - Okada, Masahiro

AU - Imai, Yasuharu

AU - Kim, Tonsok

AU - Kogita, Sachiyo

AU - Takamura, Manabu

AU - Kumano, Seishi

AU - Onishi, Hiromitsu

AU - Hori, Masatoshi

AU - Fukuda, Kazuto

AU - Hayashi, Norio

AU - Wakasa, Kenichi

AU - Sakamoto, Michiie

AU - Murakami, Takamichi

PY - 2010/10

Y1 - 2010/10

N2 - To compare enhancenent patterns of hepatocellular carcinoma (HCC) and dysplastic nodule (DN) between gadoxetate- and ferucarbotran-enhanced MRI. Patients recruited from ultrasound surveillance for HCC in chronic liver diseases were enrolled in this prospective study approved by institutional review board. Thirty-six patients with 37 histologically proven HCC, including 22 well-differentiated HCCs (wHCC), 15 moderately to poorly differentiated HCCs (mpHCCs), and 4 DNs, underwent gadoxetate-enhanced and ferucarbotran-enhanced MRI. We compared hepatobiliary phase image of gadoxetate-enhanced MRI with ferucarbotran-enhanced MR image regarding signal intensity of HCC and DN relative to surrounding liver parenchyma. We calculated contrast ratios between tumor and liver on pre-enhancement, hepatobiliary phase of gadoxetate-enhanced MRI and ferucarbotran-enhanced MRI. On ferucarbotran-enhanced MRI, all mpHCCs showed hyper-intensity, while 14 wHCCs (14/22;63%) showed iso-intensity. On hepatobiliary phase of gadoxetate-enhanced MRI, 13 mpHCCs (13/15;86%) and 20 wHCCs (20/22;91%) showed hypo-intensity. Two DNs and the other two showed iso- and hypo-intensity, respectively, on gadoxetate-enhanced MRI, whereas all DNs revealed iso-intensity on ferucarbotran-enhanced MRI. Gadoxetate-postcontrast ratio was significantly lower than ferucarbotran-postcontrast ratio in wHCC (P = 0.015). The uptake function of hepatocytes that are targeted by gadoxetate is more sensitive than that of Kupffer cells targeted by ferucarbotran in stepwise hepatocarcinogenesis.

AB - To compare enhancenent patterns of hepatocellular carcinoma (HCC) and dysplastic nodule (DN) between gadoxetate- and ferucarbotran-enhanced MRI. Patients recruited from ultrasound surveillance for HCC in chronic liver diseases were enrolled in this prospective study approved by institutional review board. Thirty-six patients with 37 histologically proven HCC, including 22 well-differentiated HCCs (wHCC), 15 moderately to poorly differentiated HCCs (mpHCCs), and 4 DNs, underwent gadoxetate-enhanced and ferucarbotran-enhanced MRI. We compared hepatobiliary phase image of gadoxetate-enhanced MRI with ferucarbotran-enhanced MR image regarding signal intensity of HCC and DN relative to surrounding liver parenchyma. We calculated contrast ratios between tumor and liver on pre-enhancement, hepatobiliary phase of gadoxetate-enhanced MRI and ferucarbotran-enhanced MRI. On ferucarbotran-enhanced MRI, all mpHCCs showed hyper-intensity, while 14 wHCCs (14/22;63%) showed iso-intensity. On hepatobiliary phase of gadoxetate-enhanced MRI, 13 mpHCCs (13/15;86%) and 20 wHCCs (20/22;91%) showed hypo-intensity. Two DNs and the other two showed iso- and hypo-intensity, respectively, on gadoxetate-enhanced MRI, whereas all DNs revealed iso-intensity on ferucarbotran-enhanced MRI. Gadoxetate-postcontrast ratio was significantly lower than ferucarbotran-postcontrast ratio in wHCC (P = 0.015). The uptake function of hepatocytes that are targeted by gadoxetate is more sensitive than that of Kupffer cells targeted by ferucarbotran in stepwise hepatocarcinogenesis.

UR - http://www.scopus.com/inward/record.url?scp=79952198514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952198514&partnerID=8YFLogxK

M3 - Article

C2 - 20882621

AN - SCOPUS:79952198514

VL - 32

SP - 903

EP - 913

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 4

ER -